Malabsorption disorders often evade early detection, and exocrine pancreatic insufficiency (EPI) is among the most commonly missed culprits behind chronic digestive symptoms — making this clinical overview from JAMA particularly timely for health-aware adults tracking their metabolic and gastrointestinal wellbeing.
EPI occurs when the pancreas fails to secrete adequate digestive enzymes — primarily lipase, protease, and amylase — to properly break down macronutrients in the small intestine. The resulting maldigestion leads to steatorrhea, weight loss, and fat-soluble vitamin deficiencies (A, D, E, and K). Underlying causes span a wide spectrum, including chronic pancreatitis, cystic fibrosis, pancreatic ductal adenocarcinoma, and post-surgical anatomical changes. Diagnosis typically involves fecal elastase-1 testing as a first-line noninvasive marker, with clinical context guiding interpretation. Treatment centers on pancreatic enzyme replacement therapy (PERT), dosed in relation to fat intake.
What makes this clinically important beyond gastroenterology is the downstream nutritional impact. Chronic fat malabsorption silently depletes fat-soluble vitamins, which are deeply implicated in bone density, immune regulation, coagulation, and cardiovascular function — areas of active concern in longevity medicine. Yet EPI frequently masquerades as irritable bowel syndrome or functional dyspepsia, leading to diagnostic delays of years in some cohorts. The fecal elastase test, while widely available, has limited sensitivity in mild-to-moderate insufficiency, meaning a normal result does not fully exclude the diagnosis. This piece from JAMA functions largely as a clinical primer rather than a novel research contribution, so its utility is largely educational and confirmatory rather than paradigm-shifting. For adults with unexplained weight loss, steatorrhea, or persistent nutrient deficiencies despite adequate intake, EPI warrants consideration as an underappreciated systemic contributor.
